CMS Proposes International Reference Pricing Models to Reduce Medicare Drug Costs
核心洞察
CMS has introduced two new drug pricing models, GUARD for Medicare (搜索) Part D and GLOBE for Part B, that would benchmark U.S. payments to prices in economically comparable countries.
The models aim to reduce inflated domestic costs for high-expenditure drugs while making critical medications more accessible to Medicare (搜索) beneficiaries.
Both proposals are designed to improve treatment adherence and relieve financial strain on the Medicare (搜索) program and its beneficiaries.
The Centers for Medicare (搜索) & Medicaid Services (CMS) has unveiled two new drug pricing models designed to reduce Medicare spending by linking U.S. payments to international price benchmarks. The proposals, known as GUARD for Medicare Part D drugs and GLOBE for Medicare Part B drugs, represent the latest initiative from the CMS Innovation Center (搜索) to address prescription drug affordability while maintaining Medicare program sustainability.
Dual Model Approach Targets Different Drug Categories
The GUARD model specifically applies to prescription drugs covered under Medicare (搜索) Part D, which typically includes medications dispensed at retail pharmacies. In contrast, the GLOBE model targets drugs reimbursed under Medicare Part B, such as injectables administered in physician offices and other provider-administered medications.
Both models would establish a framework for benchmarking U.S. Medicare (搜索) payments against prices paid in economically comparable countries, with the goal of reducing what CMS characterizes as inflated domestic costs for high-expenditure drugs.
International Reference Pricing Strategy
The international reference pricing approach represents a significant shift in Medicare (搜索) drug payment methodology. By linking U.S. payments to international benchmarks, CMS aims to leverage the pricing structures of economically similar nations to establish more cost-effective reimbursement rates for Medicare beneficiaries.
This strategy specifically targets high-expenditure drugs, suggesting that the models will focus on medications that represent the largest financial burden to the Medicare (搜索) program and its beneficiaries.
Policy Objectives Focus on Access and Sustainability
According to CMS, the models are designed to achieve multiple policy objectives centered on affordability and access. The agency stated that the initiatives are intended to make critical medications more accessible to Medicare (搜索) beneficiaries while improving treatment adherence rates.
The models also aim to relieve financial strain on both the Medicare (搜索) program itself and its beneficiaries, addressing concerns about the long-term sustainability of prescription drug coverage under Medicare.
Public Comment Period Now Open
The proposed models have been published through a notice of proposed rulemaking and are currently available for public comment via the Federal Register. This regulatory process allows stakeholders, including healthcare providers, pharmaceutical companies, patient advocacy groups, and other interested parties, to provide input on the proposed changes before final implementation.
The public comment period represents a critical phase in the regulatory process, as feedback from stakeholders may influence the final structure and implementation of both the GUARD and GLOBE models.